Rituximab biosimilar - Innovent Biologics

Drug Profile

Rituximab biosimilar - Innovent Biologics

Alternative Names: IBI 301

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 Innovent Biologics announces intention to submit regulatory application to China FDA in 2018
  • 24 Oct 2016 Innovent Biologics plans a phase I trial for B-cell lymphoma (Second-line therapy or greater) in China (IV) (NCT029452150)
  • 17 Aug 2016 Phase-I clinical trials in Chronic lymphocytic leukaemia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top